Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics office launches “Triage" pilot, aimed at providing 30-day reviews for good quality 510(k) submissions. UDI database to be tested. More regulatory news.

You may also be interested in...

The 12%: Diagnostics “Quick Reviews” Make A Mark, FDA Official Says

The first month of the diagnostics office’s “triage” pilot program has led to quicker reviews for some 510(k)s, an agency official reports. To qualify for the program's quick-review pathway, a submission must be of high quality and free of certain time-consuming complexities.

Senate Panel Approves FDA Appropriations, With Strong Words On Agency IT Systems

The Senate Appropriations Committee approves a $3.9 billion budget for the agency in fiscal 2013, including $319 million in federal funding for device activities.

FDA Dx Office Plans Pilot 510(k) ‘Triage’ Program For Early 2012

FDA’s diagnostics office will begin a pilot program in early 2012 to triage its review of 510(k) submissions based on product risk and application quality.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts